title: [SIADH and vaptans].
abstract: The vaptans are non-peptide arginine-vasopressin-receptor antagonists, that are orally and intravenously active. A few vaptans have undergone sufficient clinical development to be on the market. In the EU only tolvaptan is accepted to treat hyponatremia related to SIADH. The place of this new treatment is compared with water restriction, demeclocyclin, furosemide and urea.
authors.affiliation: Service de médecine interne générale, hôpital universitaire Erasme, Bruxelles, Belgique. guy.decaux@skynet.be
authors.forename: Guy
authors.initials: G
authors.lastname: Decaux
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects; D065092:Antidiuretic Hormone Receptor Antagonists; D014150:Antipsychotic Agents / Q000009:adverse effects; D001552:Benzazepines / Q000627:therapeutic use*; D003707:Demeclocycline / Q000009:adverse effects; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D008094:Lithium / Q000009:adverse effects; D008954:Models, Biological; D000077602:Tolvaptan
chemical_list: D000900:Anti-Bacterial Agents; D065092:Antidiuretic Hormone Receptor Antagonists; D014150:Antipsychotic Agents; D001552:Benzazepines; D006727:Hormone Antagonists; D000077602:Tolvaptan; D003707:Demeclocycline; D008094:Lithium